Randomized Phase I/II Study of Ablative Radiotherapy +/- MEDI 4736 (Durvalumab) for Medically Inoperable Early-Stage Non-Small Cell Lung Cancer
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 31 Aug 2017
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ISABR Study
- 24 Aug 2017 Planned initiation date changed from 1 Aug 2017 to 1 Jan 2018.
- 12 Jun 2017 Planned initiation date changed from 1 Jun 2017 to 1 Aug 2017.
- 16 May 2017 New trial record